文献速递药物相互作用

提高药物相互作用警示特异性的可行性研究

Improving the specificity of drug-drug interaction alerts: Can it be done?
PubMed 文献 · Am J Health Syst Pharm · 2022-01-01

该概念验证研究聚焦15种已知药物相互作用,从3个药物相互作用参考来源提取药物值集及订单和患者相关因素,用Fleiss kappa衡量值集一致性,并分类可降低风险的因素。

要点

  • 可降低风险因素中67%为订单参数,其余为患者特征。

核心结论

  • 提高触发DDI警示的药物值集一致性很重要,利用药物参考中的风险修正因素可改善警示特异性和实用性。
  • 部分因素难以操作化以减少不必要警示,但可作为背景信息支持决策。

研究设计与样本

  • 概念验证研究,聚焦15种已知药物相互作用,使用3个药物相互作用参考来源提取2个药物值集及订单和患者相关因素。
  • 采用Fleiss kappa衡量参考来源间值集的一致性,并将风险修正因素分类为订单参数或患者特征。

主要发现

  • 大多数风险修正因素(67%)被分类为订单参数。

临床怎么用

  • 临床药师可关注DDI警示触发值集的一致性,并利用药物参考中的风险修正因素(如订单参数和患者特征)提供背景信息以支持决策。

局限性

  • 部分风险修正因素可能难以操作化以减少不必要警示。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Inaccurate and nonspecific medication alerts contribute to high override rates, alert fatigue, and ultimately patient harm. Drug-drug interaction (DDI) alerts often fail to account for factors that could reduce risk; further, drugs that trigger alerts are often inconsistently grouped into value sets. Toward improving the specificity of DDI alerts, the objectives of this study were to (1) highlight the inconsistency of drug value sets for triggering DDI alerts and (2) demonstrate a method of classifying factors that can be used to modify the risk of harm from a DDI. METHODS: This was a proof-of-concept study focused on 15 well-known DDIs. Using 3 drug interaction references, we extracted 2 drug value sets and any available order- and patient-related factors for each DDI. Fleiss' kappa was used to measure the consistency of value sets among references. Risk-modifying factors were classified as order parameters (eg, route and dose) or patient characteristics (eg, comorbidities and laboratory results). RESULTS: Seventeen value sets (56%) had nonsignificant agreement. Agreement among the remaining 13 value sets was on average moderate. Thirty-three factors that could reduce risk in 14 of 15 DDIs (93%) were identified. Most risk-modifying factors (67%) were classified as order parameters. CONCLUSION: This study demonstrates the importance of increasing the consistency of drug value sets that trigger DDI alerts and how alert specificity and usefulness can be improved with risk-modifying factors obtained from drug references. It may be difficult to operationalize certain factors to reduce unnecessary alerts; however, factors can be used to support decisions by providing contextual information.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Reese T, Wright A, Liu S, et al. Improving the specificity of drug-drug interaction alerts: Can it be done? Am J Health Syst Pharm. 2022. PMID: 35136935. doi:10.1093/ajhp/zxac045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。